Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Abivax (AAVXF) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Abivax (AAVXF) over the last 4 years, with Q3 2025 value amounting to $35.1 million.

  • Abivax's Accounts Payables changed N/A to $35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year change of. This contributed to the annual value of $46.8 million for FY2024, which is 831.97% down from last year.
  • Latest data reveals that Abivax reported Accounts Payables of $35.1 million as of Q3 2025.
  • Over the past 5 years, Abivax's Accounts Payables peaked at $65.1 million during Q2 2025, and registered a low of $15.8 million during Q4 2022.
  • Over the past 4 years, Abivax's median Accounts Payables value was $46.8 million (recorded in 2024), while the average stood at $43.9 million.
  • As far as peak fluctuations go, Abivax's Accounts Payables surged by 22180.08% in 2023, and later tumbled by 782.73% in 2024.
  • Abivax's Accounts Payables (Quarter) stood at $15.8 million in 2022, then skyrocketed by 221.8% to $50.8 million in 2023, then fell by 7.83% to $46.8 million in 2024, then decreased by 25.06% to $35.1 million in 2025.
  • Its Accounts Payables was $35.1 million in Q3 2025, compared to $65.1 million in Q2 2025 and $59.5 million in Q1 2025.